Comparing the current results to its competitors, Akero Therapeutics Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.84 %, recorded in the same quarter.
Akero Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 10.19 %
Akero Therapeutics Inc 's Comment on Competition and Industry Peers
The biotechnology industry is characterized by intense competition and rapid development. Competitors include multinational pharmaceutical companies, specialized biotechnology firms, universities, and research institutions. Notable pharmaceutical competitors are AstraZeneca PLC/MedImmune LLC, Boehringer Ingelheim AG, Eisai, Inc., Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, and Takeda Pharmaceutical Company Limited. Biotechnology competitors include Aligos Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Amgen, Inc., Arrowhead Pharmaceuticals, Inc., and Boston Pharmaceuticals. Many competitors possess greater financial, technical, and human resources, more experience with clinical trials and regulatory approvals, established distribution networks, stronger brand recognition, and broader collaborative partnerships. Smaller or earlier-stage companies may also present significant competition, particularly through collaborations with larger firms. Competitors may achieve regulatory approvals or secure intellectual property rights more quickly, which could restrict the company's ability to develop or commercialize its products.
May 9, 2025
Akero Therapeutics Pushes Boundaries in Cirrhosis Treatment: Updates from SYMMETRY and SYNCHRONY Trials In an era where the implications of metabolic liver diseases are becoming increasingly pressing, Akero Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, is surging ahead with promising advancements in the treatment of compensated cirrhosis (F4 fibrosis). Recent developments have brought to light the company’s breakthrough investigational drug, efruxifermin (EFX), designed specifically for patients suffering from fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). Publication of Phase 2b SYMMETRY Trial Results On June 11, 2024, Akero Therapeutic...
March 7, 2024
Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and liver cell damage, often leading to fibrosis, cirrhosis, and even hepatocellular carcinoma. With the increasing prevalence of NASH worldwide, there is a pressing need for effective therapeutic interventions to halt or reverse the disease progression. In this article, we discuss the recent groundbreaking findings from Akero Therapeutics clinical trials, highlighting the potential of efruxifermin (EFX) as a novel treatment for NASH.Safety and Efficacy Demonstrated in Phase 2b SYMMETRY Cohort D Study:Akero Therapeutics recently published the results of the Phase 2b SYMMETRY Cohort D Study in Clinical Gastroent...
Biolinerx Ltd is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics for various diseases. Their business model revolves around the research and development of innovative drug candidates, conducting clinical trials to assess their safety and efficacy, and obtaining regulatory approvals to bring these treatments to market. They aim to generate revenue through licensing agreements, strategic collaborations, and the sale of their therapeutics to patients or healthcare providers.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Sources:
Akero Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Akero Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
